Indivior PLC (NASDAQ:INDV) Given Average Rating of “Buy” by Analysts

Indivior PLC (NASDAQ:INDV) has received a consensus rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $39.3333.

A number of analysts have issued reports on the company. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Northland Securities set a $50.00 price target on Indivior in a research report on Tuesday, January 20th.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $36.76 on Monday. The stock has a market capitalization of $4.48 billion, a PE ratio of 18.85 and a beta of 0.90. The stock has a fifty day simple moving average of $32.93 and a 200-day simple moving average of $33.42. Indivior has a twelve month low of $11.04 and a twelve month high of $41.00.

Indivior (NASDAQ:INDV) last released its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. On average, equities analysts predict that Indivior will post 3.35 earnings per share for the current year.

Insider Activity

In other Indivior news, Director Stuart A. Kingsley bought 940 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was acquired at an average cost of $31.86 per share, with a total value of $29,948.40. Following the purchase, the director owned 5,582 shares in the company, valued at approximately $177,842.52. This represents a 20.25% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

Institutional investors and hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Indivior by 43.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 317,600 shares of the company’s stock worth $11,395,000 after acquiring an additional 96,177 shares during the period. Federated Hermes Inc. purchased a new position in shares of Indivior during the 3rd quarter worth $8,120,000. Claret Asset Management Corp raised its position in shares of Indivior by 5.4% in the 3rd quarter. Claret Asset Management Corp now owns 784,588 shares of the company’s stock worth $18,916,000 after buying an additional 40,306 shares during the period. Aberdeen Group plc purchased a new position in shares of Indivior in the 3rd quarter worth $3,875,000. Finally, Victory Capital Management Inc. purchased a new position in Indivior in the third quarter valued at about $19,437,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.